Xenon Pharmaceuticals has been granted a patent for benzenesulfonamide compounds that can be used to treat diseases associated with voltage-gated sodium channels, such as epilepsy and epileptic seizure disorders. The compounds can be administered to patients to effectively treat aberrant Nav1.6 activity, including SCN8A developmental and epileptic encephalopathy. GlobalData’s report on Xenon Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Xenon Pharmaceuticals, human telomerase RT biomarker was a key innovation area identified from patents. Xenon Pharmaceuticals's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.
A recently granted patent (Publication Number: US11639351B2) discloses a method for treating diseases or conditions associated with aberrant Nav1.6 activity in patients. The diseases or conditions specifically mentioned in the patent are epilepsy, epileptic seizure disorder, and SCN8A developmental and epileptic encephalopathy (SCN8A-DEE). The method involves administering a therapeutically effective amount of a compound of formula (Ie) to the patient.
The patent claims highlight various aspects of the method. Claims 2 and 3 specify that the method is particularly applicable to epilepsy or epileptic seizure disorder. Claim 5 specifically mentions SCN8A-DEE as a target condition for treatment. Claim 6 states that the method is suitable for patients with a SCN8A mutation, which is associated with SCN8A-DEE.
Furthermore, the patent provides specific compounds that can be used in the method. Claims 7-18 list different compounds represented by specific chemical formulas. These compounds include 5-((2-((tert-butyl(methyl)amino)methyl)-6-fluorobenzyl)amino)-N-(6-fluoropyridin-2-yl)-6-methylpyridine-2-sulfonamide, 5-((2-fluoro-6-((isopropyl(methyl)-amino)methyl)benzyl)amino)-6-methyl-N-(thiazol-4-yl)pyridine-2-sulfonamide, and 5-((2-((azabicyclo[2.2.1]heptan-7-yl)methyl)-6-fluorobenzyl)amino)-3-fluoro-6-methyl-N-(thiazol-4-y1)pyridine-2-sulfonamide, among others.
In summary, the granted patent describes a method for treating diseases or conditions associated with aberrant Nav1.6 activity, specifically focusing on epilepsy, epileptic seizure disorder, and SCN8A-DEE. The method involves administering a therapeutically effective amount of specific compounds to the patient. The patent provides a range of compounds represented by chemical formulas that can be used in the method.
To know more about GlobalData’s detailed insights on Xenon Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
